10th RSA drug, Stivarga’ applied for health insurance on GIST patients
Stivarga Tab 40mg(regorafenib), a Bayer’s gastrointestinal stromal tumor(GIST) therapy, is going to be registered for the health insurance benefit from the 1st next month.
It will become the 10th drug with the risk-sharing agreement established.
The Ministry of Health and Welfare(MOHW) held the...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
